Document Detail

Insulin-like growth factor-I prevents lethal acute liver failure induced by D-galactosamine and lipopolysaccharide in rats.
MedLine Citation:
PMID:  12929583     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to evaluate the effect of insulin-like growth factor-I (IGF-I) on lethality and liver function in experimental acute liver failure. Intravenous co-administration of D-galactosamine (GalN) and lipopolysaccharide (LPS) to rats induced high mortality and marked increases in aspartate aminotransferase, alanine aminotransferase and total bilirubin, associated with hypoglycemia. One-hour pre-treatment with IGF-I significantly prevented lethality and blood parameter changes in rats. Histological examination also showed that massive hepatocellular hemorrhagic necrosis and inflammatory cell infiltration around peri-central veins in the liver, as well as shrinkage of cytoplasm and nuclear condensation, were induced by GalN plus LPS injection, but these all were improved by pre-treatment with IGF-I. Overall, this study showed that IGF-I treatment resulted in effective prevention of lethal acute liver failure in rats induced by GalN plus LPS, suggesting a therapeutic potential for IGF-I in the prevention of acute liver failure.
Takeshi Inoue; Haruo Horiai; Chizuru Aoki; Ikuo Kawamura; Mariko Ota; Hidekazu Mizuhara; Masaaki Tomoi; Seitaro Mutoh
Related Documents :
21771673 - Hepatoprotective effect of woodfordia fruticosa kurz flowers on diclofenac sodium induc...
21876983 - Sildenafil preserves diastolic relaxation after reduction by l-name and increases phosp...
4255373 - Adenosine triphosphate--dependent calcium uptake by rat submaxillary gland microsomes.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  In vivo (Athens, Greece)     Volume:  17     ISSN:  0258-851X     ISO Abbreviation:  In Vivo     Publication Date:    2003 May-Jun
Date Detail:
Created Date:  2003-08-21     Completed Date:  2004-03-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8806809     Medline TA:  In Vivo     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  293-9     Citation Subset:  IM    
Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood
Aspartate Aminotransferases / blood
Bilirubin / blood
Disease Models, Animal
Galactosamine / administration & dosage,  toxicity*
Injections, Intravenous
Insulin-Like Growth Factor I / therapeutic use*
Lipopolysaccharides / administration & dosage,  toxicity*
Liver / drug effects,  pathology*
Liver Failure, Acute / chemically induced*,  pathology*,  prevention & control*
Recombinant Proteins / therapeutic use
Reg. No./Substance:
0/Lipopolysaccharides; 0/Recombinant Proteins; 635-65-4/Bilirubin; 67763-96-6/Insulin-Like Growth Factor I; 7535-00-4/Galactosamine; EC Aminotransferases; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro.
Next Document:  Curcumin decreases the DNA adduct formation, arylamines N-acetyltransferase activity and gene expres...